Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Grants Orphan Status to Vanda, Quoin Drugs, and Lots More
Japan’s Ministry of Health, Labor and Welfare (MHLW) on June 23 doled out orphan drug designations to a raft of compounds including Vanda Pharmaceuticals’ imsidolimab for pustular psoriasis and Quoin Pharmaceuticals’ dipalmitoyl hydroxyproline for Netherton syndrome. Takeda Pharmaceutical’s vedolizumab was…
To read the full story
Related Article
- Novo’s Wegovy Nears Japan Approval as First MASH Therapy
June 1, 2026
- AstraZeneca’s Oral SERD, MSD RSV Antibody Clear Japan Panel Review
May 26, 2026
- Jazz, Nippon Zoki Ink Deal to Bring Cannabis-Derived Epilepsy Drug to Japan
April 22, 2026
- Stella Pharma Files Steboronine for Recurrent Meningioma
March 18, 2026
- Japan Grants Orphan Tag to Cannabidiol, 6 More APIs
June 10, 2024
REGULATORY
- Japan Awards Sakigake Tag to AbbVie’s Bispecific Etentamig
June 24, 2026
- Japan Grants Orphan Status to Vanda, Quoin Drugs, and Lots More
June 24, 2026
- US Opens Probe into German Drug Pricing Policies; Could Japan Be Next?
June 24, 2026
- Carvykti Earlier Use Up for Japan Panel Review on June 29
June 23, 2026
- Kampo Industry Calls for Predictable Drug Pricing to Support Stable Supply
June 23, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…